Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
50 hedge funds and large institutions have $34.8M invested in Enzo Biochem, Inc. in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 6 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
8% more capital invested
Capital invested by funds: $32.2M → $34.8M (+$2.62M)
4% less funds holding
Funds holding: 52 → 50 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
97% less call options, than puts
Call options by funds: $6K | Put options by funds: $188K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PRC
Platte River Capital
Denver,
Colorado
|
+$1.32M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$239K |
| 3 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$211K |
| 4 |
Two Sigma Investments
New York
|
+$206K |
| 5 |
Renaissance Technologies
New York
|
+$153K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.68M |
| 2 |
Millennium Management
New York
|
-$779K |
| 3 |
LMF
LMR Master Fund
Grand Cayman,
Cayman Islands
|
-$435K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$252K |
| 5 |
CCT
Chemung Canal Trust
Elmira,
New York
|
-$98.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Verition Fund Management
Greenwich,
Connecticut
| – | -$252K | -99,883 | Closed |
|
52
JP Morgan Chase
New York
| – | -$54K | -21,476 | Closed |
|
|
RFC
53
Russell Frank Company
Seattle,
Washington
| – | -$50K | -19,830 | Closed |
|
|
VKH
54
Virtu KCG Holdings
New York
| – | -$27K | -10,707 | Closed |
|
55
Citigroup
New York
| – | +$191 | +77 | +385% |
|
ENZ Hedge Fund Activity: Q4 2013 in Review
50 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2013, worth a combined $34.8M — up 8.1% from $32.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ENZ and 4 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 15 added.
The largest buyer was Platte River Capital, opening a new position worth an estimated $1.32M. The largest seller was RA Capital Management, cutting an estimated $2.68M.
- 50 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2013, down from 52 in Q3 2013.
- Funds reported $34.8M of Enzo Biochem, Inc. stock for Q4 2013, up 8.1% quarter-over-quarter.
- 4 funds opened new Enzo Biochem, Inc. positions in Q4 2013 and 6 closed out, a net change of -2 holders.
- The largest Enzo Biochem, Inc. buyer in Q4 2013 was Platte River Capital, an estimated $1.32M added.
- The largest Enzo Biochem, Inc. seller in Q4 2013 was RA Capital Management, an estimated $2.68M sold.
Based on aggregated 13F filings for Q4 2013.